Literature DB >> 15017359

Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity.

Marlys L Koschinsky1, Santica M Marcovina.   

Abstract

PURPOSE OF REVIEW: Lipoprotein(a) is a structurally and functionally unique lipoprotein consisting of the glycoprotein apolipoprotein(a) covalently linked to LDL. Lipoprotein(a) is assembled extracellularly by a two-step mechanism, still incompletely understood, in which initial non-covalent interactions between apolipoprotein(a) and apolipoprotein B precede specific disulfide bond formation. Elevated concentrations of plasma lipoprotein(a) are a risk factor for a variety of vascular diseases, including coronary heart disease, ischaemic stroke and venous thrombosis. Whereas many pathogenic mechanisms have been proposed for lipoprotein(a), it remains to be conclusively demonstrated which mechanisms are relevant to human disease. RECENT
FINDINGS: Structural and functional studies have verified that apolipoprotein(a) kringle 4 types 6-8 contain lysine binding sites of a weaker affinity for lysine analogues than kringle 4 type 10. Recent evidence has conclusively shown a role for kringle 4 types 7 and 8 in lipoprotein(a) assembly. Moreover, apolipoprotein(a) has been shown to undergo a conformational change, from a closed to an open form, which accelerates the rate of covalent lipoprotein(a) assembly. Functional studies in vitro have identified the domains in apolipoprotein(a) that mediate its inhibitory effects on fibrin clot lysis, binding to fibrin and other biological substrates, and pro-inflammatory and anti-angiogenic properties.
SUMMARY: Extensive structure-function studies of apolipoprotein(a) have begun to yield important insights into the domains in apolipoprotein(a) that mediate lipoprotein(a) assembly and the pathogenic effects of this lipoprotein. Continued investigations of these relationships will contribute critically to unravelling the many outstanding questions about lipoprotein(a) metabolism and pathophysiology.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15017359     DOI: 10.1097/00041433-200404000-00009

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  33 in total

1.  Lipoprotein(a), inflammation, and peripheral arterial disease in a community-based sample of older men and women (the InCHIANTI study).

Authors:  Stefano Volpato; Giovanni B Vigna; Mary M McDermott; Margherita Cavalieri; Cinzia Maraldi; Fulvio Lauretani; Stefania Bandinelli; Giovanni Zuliani; Jack M Guralnik; Renato Fellin; Luigi Ferrucci
Journal:  Am J Cardiol       Date:  2010-04-27       Impact factor: 2.778

2.  Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress.

Authors:  Tracie A Seimon; Marissa J Nadolski; Xianghai Liao; Jorge Magallon; Matthew Nguyen; Nicole T Feric; Marlys L Koschinsky; Richard Harkewicz; Joseph L Witztum; Sotirios Tsimikas; Douglas Golenbock; Kathryn J Moore; Ira Tabas
Journal:  Cell Metab       Date:  2010-11-03       Impact factor: 27.287

3.  HDL-C, ABCA1-mediated cholesterol efflux, and lipoprotein(a): insights into a potential novel physiologic role of lipoprotein(a).

Authors:  Calvin Yeang; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2015-05-26       Impact factor: 5.922

Review 4.  Structure, function, and genetics of lipoprotein (a).

Authors:  Konrad Schmidt; Asma Noureen; Florian Kronenberg; Gerd Utermann
Journal:  J Lipid Res       Date:  2016-04-13       Impact factor: 5.922

5.  HyperLp(a)lipoproteinaemia: unmet need of diagnosis and treatment?

Authors:  Claudia Stefanutti; Claudia Morozzi
Journal:  Blood Transfus       Date:  2016-06-29       Impact factor: 3.443

6.  Lipoprotein (a) as a Predictor of Early Stroke Recurrence in Acute Ischemic Stroke.

Authors:  Xiao-Wu Hong; Dong-Mei Wu; Jun Lu; Yuan-Lin Zheng; Wen-Jun Tu; Jing Yan
Journal:  Mol Neurobiol       Date:  2016-12-21       Impact factor: 5.590

Review 7.  Lipoprotein(a) and atherosclerosis: new perspectives on the mechanism of action of an enigmatic lipoprotein.

Authors:  Marlys L Koschinsky
Journal:  Curr Atheroscler Rep       Date:  2005-09       Impact factor: 5.113

Review 8.  Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options.

Authors:  Adam N Berman; Ron Blankstein
Journal:  Curr Cardiol Rep       Date:  2019-08-05       Impact factor: 2.931

9.  Elevated lipoprotein (a), small apolipoprotein (a), and the risk of arterial ischemic stroke in North American children.

Authors:  Neil A Goldenberg; Timothy J Bernard; Jasper Hillhouse; Jennifer Armstrong-Wells; Jeffrey Galinkin; Rhonda Knapp-Clevenger; Linda Jacobson; Santica M Marcovina; Marilyn J Manco-Johnson
Journal:  Haematologica       Date:  2013-01-24       Impact factor: 9.941

10.  Correlation analysis between serum lipoprotein (a) and the incidence of aortic valve sclerosis.

Authors:  Ning Yang; Guogang Zhang; Xiaogang Li; Liping Zhou
Journal:  Int J Clin Exp Med       Date:  2015-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.